HORIZON: Rocatinlimab Effective in Adults With Atopic Dermatitis
WEB18 hours ago · The HORIZON study is the first of eight phase 3 trials in the ROCKET clinical trial program assessing rocatinlimab in adults and adolescents with atopic dermatitis. This article originally appeared on MPR. Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of …
Temtokibart Proves Comparable to Dupilumab for Atopic …
WEB2 days ago · Temtokibart showed similar efficacy to dupilumab in treating moderate-to-severe atopic dermatitis, with faster skin hydration improvements in a phase 2a trial. Late-breaking data from the European Academy of Dermatology and Venereology (EADV) 2024 shed new light on the potential benefits of the IL-22 …
New data show Almirall´s EBGLYSS® (lebrikizumab) provided …
WEB3 days ago · BARCELONA, Spain. September 25, 2024. – More than 80 percent of adults and adolescents with moderate-to-severe atopic dermatitis who responded to lebrikizumab treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials and continued treatment for up to three years experienced sustained skin clearance with monthly maintenance dosing.Almirall S.A. (BME: ALM) announced these new long-term ...
LEO Pharma Presents Late-Breaking Results from the ... - Business …
WEB2 days ago · “These data suggest that the IL-22 pathway is central to atopic dermatitis pathogenesis, demonstrating that Type 2 inflammation is not the only relevant driver of the disease.”
Atopic dermatitis: New drug significantly improves symptoms
WEB4 days ago · EBGLYSS is now approved for adults and children 12 years or older who have moderate-to-severe atopic dermatitis. Atopic dermatitis, or eczema, is characterized by itchy skin most often located on ...
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided …
WEB3 days ago · ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin typeZORYVE was ...
New Treatment for Moderate to Severe Atopic Dermatitis Shows …
WEB(December 09, 2022) Patients with moderate to severe atopic dermatitis who participated in a clinical trial of rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in The Lancet.
Atopic dermatitis (eczema) guidelines: 2023 American Academy of …
WEBThe purpose of these guidelines is to provide evidence-based recommendations about optimal management of atopic dermatitis (AD; [atopic] eczema) in infants, children, and adults. The guidelines address the following 5 main management questions:
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic …
WEBMar 15, 2023 · Atopic dermatitis is the most prevalent chronic inflammatory skin disease, 1,2 with a worldwide prevalence of approximately 20% among children 3 and of 2 to 7% among adults. 4-7 Historical data...
Atopic dermatitis: an expanding therapeutic pipeline for a complex ...
WEBAug 20, 2021 · Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathophysiology that underlies a wide spectrum of clinical phenotypes. AD remains challenging to treat owing...
Skip to content